Skip to content
MedsAcross

Alternatives

Alternatives to Ultiva 1 mg/mL powder for injection

1 other presentations of Remifentanil 1 mg/mL powder for injection

There are 1 alternatives to this medicine in the catalogue: the same active ingredient (Remifentanil), strength (1 mg/mL) and dosage form (powder for injection) from 1 other makers or registers. The table compares packs, storage, lead time, documents and availability.

Side by side

The first row is the medicine you came from.

MedicineManufacturerRegisterPacksStorageLead timeDocumentsAvailability
Ultiva 1 mg/mL powder for injectionThis pageIntravenousMylan InstitutionalUS FDA10 vials, 10 vialsULTIVA (remifentanil hydrochloride) for Injection, for intravenous use, is supplied as follows: NDC Number Container Concentration Quantity 72078-034-01 3 mL Single-Dose Vial 1 mg lyophilized powder Box of 10 72078-035-02 5 mL Single-Dose Vial 2 mg lyophilized powder Box of 10 72078-036-05 10 mL Single-Dose Vial 5 mg lyophilized powder Box of 10 ULTIVA should be stored at 2° to 25°C (36° to 77°F).On request—Available on request
Remifentanil 1 mg/mL powder for injectionIntravenous—US FDA10 vials, 10 vialsRemifentanil Hydrochloride for injection, for intravenous use, is supplied as follows: NDC Number Strength Container Quantity 0143-9391-10 1 mg per vial 3 mL Vial Packaged in cartons of 10 0143-9392-10 2 mg per vial 5 mL Vial Packaged in cartons of 10 0143-9393-10 5 mg per vial 10 mL Vial Packaged in cartons of 10 Remifentanil Hydrochloride for injection should be stored at 2° to 25°C (36° to…On request—Available on request

Alternatives are listed for sourcing. Whether one medicine can replace another is the prescriber's decision, under the rules of the destination country.

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Back to Ultiva 1 mg/mL powder for injection

Not sure which maker to choose?

Request a quote for the medicine and we will propose the options that fit your country's import rules and timelines.